Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy...
Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer
About this item
Full title
Author / Creator
Publisher
Germany: Springer Nature B.V
Journal title
Language
English
Formats
Publication information
Publisher
Germany: Springer Nature B.V
Subjects
More information
Scope and Contents
Contents
Bone metastases are responsible for most of the morbidity associated with hormone-refractory prostate cancer (HRPC). 153Sm-ethylenediaminetetramethylene phosphonate (153Sm-EDTMP) has been approved for palliation of painful skeletal metastases. We retrospectively investigated the possible synergistic effect on survival of 153Sm-EDTMP (given to HRPC...
Alternative Titles
Full title
Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_70621140
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_70621140
Other Identifiers
ISSN
1619-7070
E-ISSN
1619-7089
DOI
10.1007/s00259-006-0343-8
